<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: profitability", fill: "#004f98"},
{source: "6: profitability", target: "6: fiscal year", fill: "#004f98"},
{source: "6: fiscal year", target: "6: further increase", fill: "#004f98"},
{source: "6: further increase", target: "6: expenditures", fill: "#004f98"},
{source: "6: expenditures", target: "6: commercialize", fill: "#004f98"},
{source: "6: commercialize", target: "6: marketed products", fill: "#004f98"},
{source: "6: marketed products", target: "6: development efforts associated with", fill: "#004f98"},
{source: "6: development efforts associated with", target: "6: seeking regulatory approvals", fill: "#004f98"},
{source: "6: seeking regulatory approvals", target: "6: development expenses associated with", fill: "#004f98"},
{source: "6: development expenses associated with", target: "6: candidates satraplatin", fill: "#004f98"},
{source: "6: candidates satraplatin", target: "6: obligations", fill: "#004f98"},
{source: "6: obligations", target: "6: milestone payments under", fill: "#004f98"},
{source: "6: milestone payments under", target: "6: license agreements", fill: "#004f98"},
{source: "6: license agreements", target: "6: product candidates", fill: "#004f98"},
{source: "6: product candidates", target: "6: additional product candidates", fill: "#004f98"},
{source: "6: profitability", target: "16: Regulatory ", fill: "#014421"},
{source: "16: Regulatory ", target: "16: authorities", fill: "#014421"},
{source: "16: authorities", target: "16: manufacturers", fill: "#014421"},
{source: "16: manufacturers", target: "16: continual regulatory review", fill: "#014421"},
{source: "16: Regulatory ", target: "24: regulatory", fill: "#f0dc82"},
{source: "24: regulatory", target: "24: development period", fill: "#f0dc82"},
{source: "24: development period", target: "24: enactment", fill: "#f0dc82"},
{source: "24: enactment", target: "24: additional statutes", fill: "#f0dc82"},
{source: "24: additional statutes", target: "24: regulations", fill: "#f0dc82"},
{source: "24: regulations", target: "24: regulatory review", fill: "#f0dc82"},
{source: "24: regulatory review", target: "24: each submitted product application may", fill: "#f0dc82"},
{source: "24: each submitted product application may", target: "24: application", fill: "#f0dc82"},
{source: "24: regulatory", target: "51: manufacture", fill: "#e2062c"},
{source: "51: manufacture", target: "51: pharmaceutical", fill: "#e2062c"},
{source: "51: pharmaceutical", target: "51: significant", fill: "#e2062c"},
{source: "51: significant", target: "51: investment", fill: "#e2062c"},
{source: "51: investment", target: "51: development", fill: "#e2062c"},
{source: "51: development", target: "51: advanced manufacturing techniques", fill: "#e2062c"},
{source: "51: manufacture", target: "START_HERE", fill: "#e2062c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Expel</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gene_regulatory_network">Gene regulatory network</a></td>
      <td>A gene (or genetic) regulatory network (GRN) is a collection of molecular regulators that interact with each other and with other substances in the cell to govern the gene expression levels of mRNA and proteins which, in turn, determine the function of the cell. GRN also play a central role in morphogenesis, the creation of body structures, which in turn is central to evolutionary developmental biology (evo-devo).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Authority">Authority</a></td>
      <td>In the fields of sociology and political science, authority is the legitimate power of a person or group over other people. In a civil state, authority is practiced in ways such a judicial branch or an executive branch of government.In the exercise of governance, the terms authority and power are inaccurate synonyms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Political_authorities">Political authorities</a></td>
      <td>Political authorities hold positions of power or influence within a system of government.  Although some are exclusive to one or another form of government, many exist within several types.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unitary_authority">Unitary authority</a></td>
      <td>A unitary authority is a local authority responsible for all local government functions within its area or performing additional functions that elsewhere are usually performed by a higher level of sub-national government or the national government.\nTypically unitary authorities cover towns or cities which are large enough to function independently of a council or other authority.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/With_Authority!">With Authority!</a></td>
      <td>With Authority! was an online wrestling game created by Genetic Anomalies in conjunction with THQ and the World Wrestling Federation (WWF).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Virtual_International_Authority_File">Virtual International Authority File</a></td>
      <td>The Virtual International Authority File (VIAF) is an international authority file. It is a joint project of several national libraries and operated by the Online Computer Library Center (OCLC).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Combined_authority">Combined authority</a></td>
      <td>A combined authority is a type of local government institution introduced in England outside Greater London by the Local Democracy, Economic Development and Construction Act 2009. Combined authorities are created voluntarily and allow a group of local authorities to pool appropriate responsibility and receive certain delegated functions from central government in order to deliver transport and economic policy more effectively over a wider area.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PHARMION CORP      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>In  addition  to other information included in this report, the     <font color="blue">following factors should</font> be considered in evaluating our business and future     prospects</td>
    </tr>
    <tr>
      <td>Risks Related to Our Business       We have a history of net losses, and may not maintain <font color="blue">profitability</font> in the     future</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had an <font color="blue">accumulated</font>     deficit of dlra135dtta8 million</td>
    </tr>
    <tr>
      <td>Although we achieved <font color="blue">profitability</font> for our 2005     <font color="blue">fiscal year</font>, we expect to <font color="blue">further increase</font> our <font color="blue"><font color="blue">expenditure</font>s</font> to:         •  <font color="blue">commercialize</font> our <font color="blue">marketed products</font>;         •  support our <font color="blue"><font color="blue">development</font> efforts associated with</font> completing clinical     trials and <font color="blue">seeking <font color="blue"><font color="blue">regulatory</font> approvals</font></font> of our products, including     <font color="blue"><font color="blue">development</font> expenses associated with</font> our recently-acquired product     <font color="blue">candidates</font>, <font color="blue">satraplatin</font> and MGCD0103;         •  satisfy our <font color="blue">obligations</font> to make <font color="blue">milestone payments under</font> the existing     <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> for our <font color="blue"><font color="blue">product candidate</font>s</font>; and         •  acquire <font color="blue">additional</font> <font color="blue"><font color="blue">product candidate</font>s</font> or companies</td>
    </tr>
    <tr>
      <td>Accordingly, we do not expect to maintain <font color="blue">profitability</font> during our     2006  fiscal  year  and we are unsure as to when we will again achieve     <font color="blue">profitability</font> for any substantial period of time</td>
    </tr>
    <tr>
      <td>If we fail to achieve     <font color="blue">profitability</font> within the time frame expected <font color="blue">by investors</font> or securities     analysts, the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> may decline</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">existing commercial</font> business is <font color="blue">largely dependent on</font> the success of     Vidaza</td>
    </tr>
    <tr>
      <td><font color="blue">Sales <font color="blue">of Vidaza </font></font>account for a <font color="blue">significant</font> portion of our <font color="blue">total product</font>     sales</td>
    </tr>
    <tr>
      <td>For  the <font color="blue">fiscal year</font> ended <font color="blue">December </font>31, 2005, Vidaza net sales     represented 57prca of our <font color="blue">total net sales</font></td>
    </tr>
    <tr>
      <td>Vidaza sales have not increased     <font color="blue">significant</font>ly over the <font color="blue">past several calendar quarters</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">Vidaza     </font>will  face  increased <font color="blue">competition from</font> Revlimid^tm, which was recently     approved for marketing by the FDA as a treatment for a subset of low-risk     MDS patients, and we <font color="blue">may face <font color="blue">competition from</font> new therapeutics</font> for treating     MDS <font color="blue">under <font color="blue">development</font> by</font> our <font color="blue">competitors</font> that are currently being considered     for <font color="blue">approval by</font> the FDA The <font color="blue">commercial success</font> <font color="blue">of Vidaza </font>and future growth     <font color="blue">in Vidaza </font>sales will depend, among other things, upon:         •  continued <font color="blue">acceptance</font> by <font color="blue">regulators</font>, physicians, patients and other key     decision-makers as a safe, superior <font color="blue">therapeutic as compared</font> to currently     existing or <font color="blue">future <font color="blue">treatments</font></font> for MDS;                                         24       _________________________________________________________________    [78]Table of <font color="blue">Contents       </font>  •  the success of our current survival <font color="blue">clinical trial</font> <font color="blue">for Vidaza </font>in MDS;         •  our ability to achieve a <font color="blue">marketing authorization</font> for <font color="blue">Vidaza <font color="blue">in Europe </font>    </font>and in other countries; and         •  our ability to expand the <font color="blue"><font color="blue">indication</font>s</font> for which we can market Vidaza</td>
    </tr>
    <tr>
      <td>As a consequence, we cannot make assurances that Vidaza will gain     <font color="blue">increased market <font color="blue">acceptance</font> from members</font> of the <font color="blue">medical community</font> or that     the <font color="blue">acceptance</font> <font color="blue">of Vidaza </font>we have observed thus far will be maintained</td>
    </tr>
    <tr>
      <td><font color="blue">Even     </font>if Vidaza does gain increased market <font color="blue">acceptance</font>, we may not be able to     maintain  that  market  <font color="blue">acceptance</font> over time if these <font color="blue">new products</font> are     introduced and are more favorably received than Vidaza or render <font color="blue">Vidaza     </font>obsolete</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities</font> in our markets subject <font color="blue">approved products</font> and     <font color="blue"><font color="blue">manufacture</font>rs</font>  of  approved  products  to <font color="blue">continual <font color="blue"><font color="blue">regulatory</font> review</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Previously  </font>unknown  problems, such as unacceptable toxicities or side     effects, may only be discovered after a product has <font color="blue">been approved</font> and used     in an increasing number of patients</td>
    </tr>
    <tr>
      <td>If this occurs, <font color="blue">regulatory</font> <font color="blue">authorities</font>     may  <font color="blue">impose labeling <font color="blue">restrictions</font> on</font> the product that <font color="blue">could affect</font> its     <font color="blue">commercial viability</font> or could require withdrawal of the <font color="blue">product from</font> the     market</td>
    </tr>
    <tr>
      <td>Accordingly, there is a risk that we <font color="blue">will discover such previously</font>     <font color="blue">unknown problems associated with</font> the use <font color="blue">of Vidaza </font>in patients, which could     limit sales growth or cause sales <font color="blue">of Vidaza </font>to decline</td>
    </tr>
    <tr>
      <td>We may not receive <font color="blue"><font color="blue">regulatory</font> approvals</font> for our <font color="blue"><font color="blue">product candidate</font>s</font>,     including thalidomide, <font color="blue">satraplatin</font> or, outside of the United States, for     Vidaza, or approvals may be delayed</td>
    </tr>
    <tr>
      <td>Our ability to fully <font color="blue">commercialize</font> thalidomide and <font color="blue">satraplatin</font> is     subject to <font color="blue">regulatory</font> <font color="blue">approval by</font> <font color="blue">government</font>al <font color="blue">authorities</font> <font color="blue">in Europe </font>and our     other markets, and our ability to <font color="blue">commercialize</font> Vidaza outside the US is     subject to <font color="blue">regulatory</font> <font color="blue">approval by</font> <font color="blue">government</font>al <font color="blue">authorities</font> <font color="blue">in Europe </font>and     elsewhere</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">regulatory</font> review</font> and <font color="blue">approval process</font> to obtain marketing     approval, even for a drug that is approved in other <font color="blue">jurisdictions</font>, takes     many years and requires the <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>process can <font color="blue">vary <font color="blue">substantially</font> <font color="blue">based on</font></font> the type, complexity, novelty and     <font color="blue">indication</font> of the <font color="blue"><font color="blue">product candidate</font> involved</font></td>
    </tr>
    <tr>
      <td>Changes in the <font color="blue">regulatory</font>     approval policy during the <font color="blue"><font color="blue">development</font> period</font>, changes in or the <font color="blue">enactment</font>     of <font color="blue"><font color="blue">additional</font> statutes</font> or <font color="blue">regulations</font>, or changes in <font color="blue"><font color="blue">regulatory</font> review</font> for     <font color="blue">each submitted product <font color="blue">application</font> may</font> cause delays in the approval or     rejection of an <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> <font color="blue">authorities</font> have substantial     <font color="blue">discretion</font> in the <font color="blue">approval process</font> and may refuse to accept any <font color="blue">application</font>     or may decide that data is insufficient for approval and require <font color="blue">additional</font>     pre-clinical,   clinical   or  other  studies</td>
    </tr>
    <tr>
      <td>In  addition,  varying     <font color="blue">interpretations</font> of the data obtained from pre-clinical and <font color="blue">clinical testing</font>     by <font color="blue">regulatory</font> <font color="blue">authorities</font> could delay, limit or prevent <font color="blue">regulatory</font> approval     of a <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>In July 2005, we announced the <font color="blue">completion</font> of the <font color="blue">scientific advice</font>     <font color="blue">procedure with</font> the EMEA regarding the <font color="blue">clinical data</font> needed to support a     <font color="blue">marketing authorization</font> for thalidomide in relapsed/ refractory multiple     myeloma</td>
    </tr>
    <tr>
      <td>Based on this <font color="blue">scientific advice</font>, we initiated a <font color="blue">four arm randomized</font>     study of 400-500 patients in this <font color="blue">indication</font> in <font color="blue">February </font>2006</td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2006, we announced that, pending     further  data  review  and  <font color="blue">communication with</font> the European <font color="blue">regulatory</font>     <font color="blue">authorities</font>, we expect that the results of a pivotal <font color="blue">Phase III </font>multiple     myeloma trial conducted by <font color="blue">Celgene Corporation </font>will form the basis of a new     MAA for thalidomide in the treatment of first-line treatment of multiple     myeloma in Europe</td>
    </tr>
    <tr>
      <td>Just before our <font color="blue">announcement</font>, Celgene announced that the     study met the pre-specified interim endpoint for efficacy and would be     stopped</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that the results of this trial or our ongoing     <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">thalidomide will support</font> our <font color="blue">application</font>s for these     <font color="blue"><font color="blue">regulatory</font> approvals</font></td>
    </tr>
    <tr>
      <td><font color="blue">In November </font>2005, we withdrew our <font color="blue">previously filed</font> MAA with the EMEA     for Vidaza, <font color="blue">based on</font> the EMEA’s stated view that <font color="blue">additional</font> <font color="blue">clinical data</font>     would be required before it can reach an <font color="blue">opinion on whether</font> or not <font color="blue">Vidaza     </font>should be <font color="blue">approved as</font> a treatment of MDS We have <font color="blue">previously initiated</font> a     <font color="blue">clinical study</font> of 354 high-risk MDS <font color="blue"><font color="blue">patients with</font> overall survival as</font> the     <font color="blue">primary endpoint</font> of the study, which we expect to complete in 2007</td>
    </tr>
    <tr>
      <td>If the     results of this study are positive, we intend to submit a new MAA for <font color="blue">Vidaza     </font>with the EMEA <font color="blue">based on</font> data from this study</td>
    </tr>
    <tr>
      <td>In addition, we have recently acquired <font color="blue">marketing rights</font> to <font color="blue">satraplatin</font>     <font color="blue">in Europe </font>and certain other countries from <font color="blue"><font color="blue">GPC Biotech AG </font>Satraplatin </font>is     the subject of an ongoing <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font> as</font> a second-                                         25       _________________________________________________________________    [79]Table of <font color="blue">Contents       </font><font color="blue">line chemotherapy treatment</font> for <font color="blue">patients with</font> HRPC Based <font color="blue">on data from</font> this     trial, we expect to file an <font color="blue">MAA <font color="blue">in Europe </font></font>in 2007</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that the results of these studies <font color="blue">for Vidaza </font>or     <font color="blue">satraplatin</font> will be positive or, even if either study is positive, that the     EMEA will accept the results of the <font color="blue">studies as</font> the basis for a marketing     approval</td>
    </tr>
    <tr>
      <td>The  timing  of  our <font color="blue">submissions</font>, the outcome of <font color="blue">reviews by</font> the     applicable  <font color="blue">regulatory</font>  <font color="blue">authorities</font>  in  <font color="blue">each relevant market</font>, and the     <font color="blue">initiation</font> and <font color="blue">completion</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> are subject to <font color="blue">uncertainty</font>,     change and <font color="blue">unforeseen delays</font></td>
    </tr>
    <tr>
      <td>Moreover, favorable results in <font color="blue">later stage</font>     clinical  trials  do not ensure <font color="blue">regulatory</font> approval to <font color="blue">commercialize</font> a     product</td>
    </tr>
    <tr>
      <td>Some  companies  that have believed their products performed     <font color="blue">satisfactorily</font>  in  clinical  trials have <font color="blue">nonetheless failed</font> to obtain     <font color="blue">regulatory</font>  approval  of their products</td>
    </tr>
    <tr>
      <td>We will not be able to market     thalidomide, Vidaza or <font color="blue">satraplatin</font> in any country where the drug is not     approved, and if thalidomide, Vidaza or <font color="blue">satraplatin</font> is not approved for sale     in a market where we have acquired rights to the product, we will only be     able to sell it in such market, if at all, on a <font color="blue"><font color="blue">compassionate</font> use</font> or named     patient basis, which will limit sales</td>
    </tr>
    <tr>
      <td>Thalidomide’s history of causing <font color="blue">birth defects may prevent</font> it <font color="blue">from becoming</font>     <font color="blue">commercially successful</font></td>
    </tr>
    <tr>
      <td>At the time thalidomide first came on the market in the late 1950’s     and into the early 1960’s, it was not known that the drug could cause birth     defects in <font color="blue">babies born</font> to women who had taken the <font color="blue">drug while pregnant</font></td>
    </tr>
    <tr>
      <td>The majority of these births were in the UK and Germany, two     of  our  <font color="blue">largest target markets</font> for sales of thalidomide</td>
    </tr>
    <tr>
      <td>As a result,     thalidomide’s historical reputation in our target markets may delay or     prevent <font color="blue">regulatory</font> approval <font color="blue">in Europe </font>or may present a substantial barrier     to its market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Thalidomide’s potential for causing <font color="blue">severe birth</font>     defects and its <font color="blue">negative historical reputation may limit</font> the extent of its     market <font color="blue">acceptance</font> among both doctors and patients, despite the efficacy that     it has <font color="blue">been proven</font> to have in <font color="blue">patients afflicted with</font> a number of <font color="blue">different</font>     diseases</td>
    </tr>
    <tr>
      <td>In addition, any report of a <font color="blue">birth defect attributed</font> to the     <font color="blue">current use</font> of thalidomide could result in a material decrease in our sales     of thalidomide, and may result in the <font color="blue">forced withdrawal</font> of <font color="blue">thalidomide from</font>     the market</td>
    </tr>
    <tr>
      <td>If the <font color="blue">third party</font> <font color="blue"><font color="blue">manufacture</font>rs</font> upon whom we rely fail to produce our     products in the volumes that we require on a <font color="blue">timely basis</font>, or to <font color="blue">comply with</font>     stringent <font color="blue">regulations</font> applicable to <font color="blue">pharmaceutical</font> drug <font color="blue"><font color="blue">manufacture</font>rs</font>, we     <font color="blue">may face delays</font> in the <font color="blue">commercialization</font> of, or be unable to meet demand     for, our products and <font color="blue">may lose <font color="blue">potential revenues</font></font></td>
    </tr>
    <tr>
      <td>We do not <font color="blue">manufacture</font> any of our products and we do not plan to     develop  any  <font color="blue">capacity</font>  to  do so</td>
    </tr>
    <tr>
      <td>We have contracted with third-party     <font color="blue"><font color="blue">manufacture</font>rs</font>  to <font color="blue">manufacture</font> each of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of     <font color="blue">pharmaceutical</font>  products  requires  <font color="blue">significant</font>  expertise and capital     <font color="blue">investment</font>, including the <font color="blue">development</font> of <font color="blue">advanced <font color="blue">manufacturing</font> techniques</font>     and  process  controls</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>of <font color="blue">pharmaceutical</font> products often     encounter <font color="blue"><font color="blue">difficult</font>ies</font> in production, <font color="blue">especially</font> in scaling up initial     production</td>
    </tr>
    <tr>
      <td>These problems include <font color="blue"><font color="blue">difficult</font>ies</font> with production costs and     yields, quality control and assurance and shortages of <font color="blue">qualified personnel</font>,     <font color="blue">as well as <font color="blue">compliance with</font> strictly enforced federal</font>, state and foreign     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our third-party <font color="blue"><font color="blue">manufacture</font>rs</font> may not perform as agreed or may     terminate their <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font> <font color="blue">authorities</font>  in  our  markets require that drugs be     <font color="blue">manufacture</font>d, packaged and labeled in conformity with cGMP <font color="blue">regulations</font> and     <font color="blue">guidelines</font></td>
    </tr>
    <tr>
      <td>In  addition,  before  any  <font color="blue">product batch</font> produced by our     <font color="blue"><font color="blue">manufacture</font>rs</font> can be shipped, it <font color="blue">must conform</font> to <font color="blue">release specifications</font>     pre-<font color="blue">approved by</font> <font color="blue">regulators</font> for the content of the <font color="blue">pharmaceutical</font> product</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">manufacturing</font> process</font> <font color="blue">for Vidaza </font>is very complex</td>
    </tr>
    <tr>
      <td>There is a risk that     our <font color="blue"><font color="blue">manufacture</font>rs</font> will not <font color="blue">comply with</font> all applicable <font color="blue">regulatory</font> standards,     and  may  not be able to <font color="blue">manufacture</font> Vidaza on a <font color="blue">commercial scale</font> that     <font color="blue">conforms on</font> a <font color="blue">consistent basis</font> to our <font color="blue">release specifications</font> <font color="blue">approved by</font> the     FDA             To date, we have <font color="blue">relied on sole sources</font> for the <font color="blue">manufacture</font> of our     products and, although we are in the process of qualifying a second-source     <font color="blue">manufacture</font>r for the fill and finishing processes for Vidaza, we do not have     <font color="blue">operational alternate <font color="blue">manufacturing</font> <font color="blue">facilities</font></font> in place at this time</td>
    </tr>
    <tr>
      <td>The     number of third-party                                         26       _________________________________________________________________    [80]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">manufacture</font>rs</font>  with  the  expertise, required <font color="blue"><font color="blue">regulatory</font> approvals</font> and     <font color="blue">facilities</font> to <font color="blue">manufacture</font> bulk drug substance on a <font color="blue">commercial scale</font> is     extremely limited, and it would take a <font color="blue">significant</font> amount of time to arrange     for alternative <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>If we need to change to other commercial     <font color="blue"><font color="blue">manufacture</font>rs</font>, the FDA and comparable foreign <font color="blue">regulators</font> must approve these     <font color="blue"><font color="blue">manufacture</font>rs</font>’  <font color="blue">facilities</font> and processes prior to our use, which would     require new testing and compliance <font color="blue">inspections</font>, and the new <font color="blue"><font color="blue">manufacture</font>rs</font>     would  have  to  be educated in or <font color="blue"><font color="blue">independent</font>ly</font> develop the processes     <font color="blue">necessary</font> for the production of our products</td>
    </tr>
    <tr>
      <td>Any of these factors could cause us to delay or suspend clinical     trials, <font color="blue">regulatory</font> <font color="blue">submissions</font>, required approvals or <font color="blue">commercialization</font> of     our products or <font color="blue"><font color="blue">product candidate</font>s</font>, entail higher costs and result in our     being unable to <font color="blue"><font color="blue">effective</font>ly</font> <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Furthermore, if our     third-party <font color="blue"><font color="blue">manufacture</font>rs</font> fail to deliver the required <font color="blue">commercial quantities</font>     of  bulk  drug  substance or finished <font color="blue">product on</font> a <font color="blue">timely basis</font> and at     <font color="blue">commercially reasonable prices</font>, and we are unable to <font color="blue">promptly find one</font> or     more replacement <font color="blue"><font color="blue">manufacture</font>rs</font> capable of <font color="blue">production at</font> a <font color="blue">substantially</font>     <font color="blue">equivalent cost</font>, in <font color="blue">substantially</font> equivalent volume and on a <font color="blue">timely basis</font>,     we <font color="blue">would likely</font> be unable to meet demand for our products and we would lose     <font color="blue">potential revenues</font></td>
    </tr>
    <tr>
      <td>Moreover, failure of our <font color="blue">third party</font> <font color="blue"><font color="blue">manufacture</font>rs</font> to     <font color="blue">comply with</font> applicable <font color="blue">regulations</font> could result in sanctions being imposed     on  us,  including  fines, injunctions, civil penalties, suspension or     withdrawal of approvals, license revocation, seizures or recalls of product     <font color="blue">candidates</font> or products, operating <font color="blue">restrictions</font> and <font color="blue">criminal prosecutions</font>,     any of which could <font color="blue">significant</font>ly and <font color="blue">adversely affect supplies</font> <font color="blue">of Vidaza </font>and     our other products</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in our operating results <font color="blue">could affect</font> the price of our common     stock</td>
    </tr>
    <tr>
      <td>Our operating results may vary <font color="blue">significant</font>ly from period to <font color="blue">period due</font>     to many factors, including the amount and timing of sales of our products,     <font color="blue">underlying demand</font> and <font color="blue">wholesaler buying patters</font> for Vidaza, the <font color="blue">availability</font>     and timely delivery of a <font color="blue">sufficient supply</font> of our products, the timing and     amount of operating expenses, <font color="blue">particularly</font> for <font color="blue">development</font> <font color="blue">activities</font>,     <font color="blue">announcement</font>s regarding <font color="blue">clinical trial</font> results and <font color="blue">product introductions by</font>     us  or  our  <font color="blue">competitors</font>,  the  <font color="blue">availability</font> and timing of third-party     <font color="blue">reimbursement</font> and the timing of <font color="blue">regulatory</font> <font color="blue">submissions</font> and approvals</td>
    </tr>
    <tr>
      <td>If our     operating results do not match the <font color="blue">expectations</font> of <font color="blue">securities analysts</font> and     <font color="blue">investors as</font> a result of these and other factors, the <font color="blue">trading price</font> of our     <font color="blue"><font color="blue">common stock</font> will likely decrease</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">effective</font> tax rate</font> has, and <font color="blue">likely will continue</font> to, vary <font color="blue">significant</font>ly     from period to period</td>
    </tr>
    <tr>
      <td><font color="blue">Increases </font>in our <font color="blue"><font color="blue">effective</font> tax rate</font> would have a     negative effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">effective</font> tax rate</font> has varied <font color="blue">significant</font>ly since our inception</td>
    </tr>
    <tr>
      <td>This is <font color="blue">largely due</font> to the fact that we are subject to <font color="blue"><font color="blue">income tax</font>es</font> in a     number of <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">tax provision</font> for <font color="blue">each country</font> is <font color="blue">based on</font>     pre-tax earnings or losses in <font color="blue">each specific country</font>, and tax losses in one     <font color="blue">country cannot</font> be used to <font color="blue">offset taxable income</font> in other countries</td>
    </tr>
    <tr>
      <td>As a     result, our <font color="blue">consolidated</font> <font color="blue"><font color="blue">effective</font> tax rate</font> has <font color="blue">historically</font> been far in     excess of US <font color="blue">statutory tax rates</font></td>
    </tr>
    <tr>
      <td>We expect this <font color="blue">trend will continue</font> for     the <font color="blue">foreseeable future</font>             Since our inception, we have had minimal or <font color="blue">no provision</font> for US     <font color="blue"><font color="blue">income tax</font>es</font> due to <font color="blue">incurring losses</font> <font color="blue">in the US </font>or, in the case of 2005,     <font color="blue">utilizing tax net</font> operating <font color="blue">loss <font color="blue">carryforwards</font></font> to <font color="blue">offset taxable income</font> in     the US <font color="blue">As of <font color="blue">December </font></font>31, 2005 we had <font color="blue">approximately</font> dlra131 million in US     federal  and  foreign  tax <font color="blue">loss <font color="blue">carryforwards</font></font>, including <font color="blue">approximately</font>     dlra35 million in US <font color="blue">loss <font color="blue">carryforwards</font></font> and dlra86 million in Swiss tax loss     <font color="blue">carryforwards</font></td>
    </tr>
    <tr>
      <td>US net operating <font color="blue">loss <font color="blue">carryforwards</font></font> are subject to “change     of ownership” <font color="blue">limitations</font> under Sections 382 of the <font color="blue">Internal Revenue Code     </font>and  may  also  be subject to various other <font color="blue">limitations</font> on the amounts     utilized</td>
    </tr>
    <tr>
      <td>A change in ownership last occurred in 2001, but that change had     <font color="blue">minimal impact on</font> the <font color="blue">availability</font> of net operating <font color="blue">loss <font color="blue">carryforwards</font></font> as     the  majority  of the losses were <font color="blue">incurred subsequent</font> to the change in     ownership</td>
    </tr>
    <tr>
      <td>We anticipate that a second change in <font color="blue">ownership may</font> occur in     2006</td>
    </tr>
    <tr>
      <td>If so, the amount of net operating <font color="blue">loss <font color="blue">carryforwards</font></font> available in     2006 and in <font color="blue">subsequent years may</font> be reduced <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>If we maintain     <font color="blue">profitability</font>  in  the  US, the reduction in the <font color="blue">availability</font> of net     operating <font color="blue">loss <font color="blue">carryforwards</font></font> may result in an increase in US <font color="blue">income tax</font>     expense and our overall <font color="blue"><font color="blue">effective</font> tax rate</font></td>
    </tr>
    <tr>
      <td>This in turn would result in a     reduction in our net income and <font color="blue">net income per</font> share <font color="blue">beginning with</font> the     quarter of <font color="blue">implementation</font></td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________    [81]Table of <font color="blue">Contents       </font>If we breach any of the <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> under which</font> we license <font color="blue">commercialization</font>     rights to products or <font color="blue"><font color="blue">technology</font> from others</font>, we <font color="blue">could lose license rights</font>     that are important to our business</td>
    </tr>
    <tr>
      <td>We license <font color="blue">commercialization</font> rights to products and <font color="blue">technology</font> that     are important to our business, and we expect to <font color="blue">enter into</font> similar licenses     in the future</td>
    </tr>
    <tr>
      <td>For instance, we acquired rights to <font color="blue">certain intellectual</font>     property and <font color="blue">technology</font> for Vidaza, thalidomide, <font color="blue">satraplatin</font> and MGCD0103     through exclusive licensing arrangements with third parties</td>
    </tr>
    <tr>
      <td>Under these     licenses we are subject to <font color="blue">commercialization</font> and <font color="blue">development</font>, sublicensing,     royalty, milestone payments, insurance and other <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">comply with</font> any of these <font color="blue">requirements</font>, or <font color="blue">otherwise breach</font> these license     <font color="blue"><font color="blue">agreement</font>s</font>, the <font color="blue">licensor may</font> have the right to terminate the license in     whole or to terminate the exclusive nature of the license</td>
    </tr>
    <tr>
      <td>Loss of any of     these licenses or the <font color="blue"><font color="blue">exclusivity</font> rights provided therein <font color="blue">could harm</font></font> our     <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>We face substantial competition, which may result in <font color="blue">others <font color="blue">commercializing</font></font>     <font color="blue">competing products</font> before or more <font color="blue"><font color="blue">successfully</font> than</font> we do</td>
    </tr>
    <tr>
      <td>Our industry is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend on</font> our     ability to acquire, develop and <font color="blue">commercialize</font> products and our ability to     establish and maintain markets for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">competitors</font> in     North America, Europe and elsewhere include major <font color="blue">pharmaceutical</font> companies,     specialized <font color="blue">pharmaceutical</font> companies and bio<font color="blue">technology</font> firms, <font color="blue">universities</font>     and other <font color="blue">research institutions</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have <font color="blue">substantially</font>     greater research and <font color="blue">development</font> <font color="blue">capabilities</font> and experience, and greater     <font color="blue">manufacturing</font>, marketing and financial resources, than we do</td>
    </tr>
    <tr>
      <td>Accordingly,     our <font color="blue">competitors</font> may develop or <font color="blue">license products</font> or other <font color="blue">novel technologies</font>     that are more <font color="blue">effective</font>, safer or <font color="blue">less costly than</font> our <font color="blue">existing products</font> or     products that are being developed by us, or may obtain <font color="blue">regulatory</font> approval     for products before we do</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">development</font> by <font color="blue">others may</font> render our     products or <font color="blue"><font color="blue">product candidate</font>s</font> noncompetitive</td>
    </tr>
    <tr>
      <td>Other <font color="blue">pharmaceutical</font> companies may develop <font color="blue">generic versions</font> of our     products that are not subject to <font color="blue">patent protection</font> or otherwise subject to     <font color="blue"><font color="blue">orphan drug</font> <font color="blue">exclusivity</font></font> or other <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>In particular, because     we have only limited <font color="blue">patent protection</font> for thalidomide, we face substantial     <font color="blue">competition from</font> <font color="blue">generic versions</font> of <font color="blue">thalidomide throughout</font> Europe and other     <font color="blue">territories</font> in which we sell thalidomide without <font color="blue"><font color="blue">orphan drug</font> <font color="blue">exclusivity</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font>and other pressures to reduce <font color="blue">pharmaceutical</font> costs may result     in <font color="blue">physicians writing <font color="blue">prescription</font>s</font> for these <font color="blue">generic products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increased     </font><font color="blue">competition from</font> the sale of competing generic <font color="blue">pharmaceutical</font> products could     cause a material decrease in sales of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">primary competition</font> and <font color="blue">potential competition</font> for our products     currently are:         •  Vidaza: Thalomid^® and Revlimid^tm, <font color="blue">each from</font> Celgene, and Dacogen^tm     from Supergen Inc, with <font color="blue">marketing rights</font> held by MGI Pharma, Inc, which     like Vidaza, is a <font color="blue">demethylating agent</font>;         •  Thalidomide: Velcade^tm from Millennium Pharmaceuticals Inc, and     Revlimid^tm from Celgene Corporation, in addition to competing sales of     other versions of thalidomide described above;          •   Satraplatin:  Emcyt^® from Pfizer Inc</td>
    </tr>
    <tr>
      <td>; Novantrone^® from (osi)     <font color="blue">pharmaceutical</font>s/  Serono,  Inc</td>
    </tr>
    <tr>
      <td>;  Quadramet^® from Schering AG/Cytogen     Corporation; Metastron^® from Amersham Health/ Medi-Physics, Inc</td>
    </tr>
    <tr>
      <td>; and     Taxotere^® from Sanofi Aventis SA, <font color="blue">as approved drugs</font></td>
    </tr>
    <tr>
      <td>There are other agents     in <font color="blue">development</font> for <font color="blue">prostate cancer</font>, including pemetrexel from <font color="blue">Eli Lilly </font>and     Company;  <font color="blue">calcitriol</font>  from  Novacea,  Inc</td>
    </tr>
    <tr>
      <td>;  Provenge^®  from Dendreon     Corporation;  <font color="blue">ixabepilone</font>  from Bristol-Myers Squibb Co</td>
    </tr>
    <tr>
      <td>; Avastin from     <font color="blue">Genentech Inc</font></td>
    </tr>
    <tr>
      <td>; Velcade^® from <font color="blue">Millenium Pharmaceuticals Inc</font></td>
    </tr>
    <tr>
      <td>;     and Arixtra, from <font color="blue">GlaxoSmithKline</font> plc; and         •  Refludan: Argatroban, from <font color="blue">GlaxoSmithKline</font></td>
    </tr>
    <tr>
      <td>Dacogen is <font color="blue">currently under review</font> for <font color="blue">regulatory</font> <font color="blue">approval by</font> the FDA     and Revlimid was <font color="blue">recently <font color="blue">approved by</font></font> the FDA as a treatment for <font color="blue">certain low</font>     risk MDS patients and is <font color="blue">currently under review</font> for <font color="blue">regulatory</font> <font color="blue">approval by</font>     the EMEA In addition to these products, there are <font color="blue">additional</font> products in     clinical                                         28       _________________________________________________________________    [82]Table of <font color="blue">Contents       </font><font color="blue">development</font> for the treatment of MDS and the <font color="blue">enrollment</font> of patients in     <font color="blue"><font color="blue">clinical trial</font>s</font> for these <font color="blue"><font color="blue">products may</font> reduce</font> the number of patients that     will receive Vidaza treatment</td>
    </tr>
    <tr>
      <td>We <font color="blue">also face competition</font> <font color="blue">for Vidaza </font>from     <font color="blue">traditional therapies</font> for the treatment of MDS, including the use of blood     <font color="blue">transfusions</font> and <font color="blue">growth factors</font></td>
    </tr>
    <tr>
      <td>In addition, MGCD0103, a histone <font color="blue">deacetylase</font> (HDAC) inhibitor recently     <font color="blue">licensed by us from</font> <font color="blue">MethylGene Inc</font>, is in a very <font color="blue">early stage</font> of <font color="blue">development</font>     and we do not anticipate completing <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>However, several other HDAC inhibitors are in more advanced <font color="blue"><font color="blue">clinical trial</font>s</font>,     including SAHA from Merck &amp; Co, Inc, and may reach the market before     MGCD0103</td>
    </tr>
    <tr>
      <td>If  this  occurs,  the <font color="blue">market potential</font> for MGCD0103 may be     <font color="blue">significant</font>ly reduced</td>
    </tr>
    <tr>
      <td>The timing of <font color="blue">customer purchases</font> and the resulting <font color="blue">product shipments</font> have a     <font color="blue">significant</font> impact on the amount of <font color="blue">product sales</font> that we recognize in a     <font color="blue">particular period</font></td>
    </tr>
    <tr>
      <td>The majority of our sales <font color="blue">of Vidaza </font>in the <font color="blue">United States </font>are made to     <font color="blue">independent</font>  <font color="blue">pharmaceutical</font>  <font color="blue">wholesalers</font>, including <font color="blue">specialty oncology</font>     distributors, which, in turn, resell the product to an end <font color="blue">user customer</font>     (normally  a  clinic,  hospital, alternative healthcare facility or an     <font color="blue">independent</font> pharmacy)</td>
    </tr>
    <tr>
      <td><font color="blue">Inventory </font>in the <font color="blue"><font color="blue">distribution channel</font> consists</font> of     inventory held by these <font color="blue">wholesalers</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product sales</font> in a particular     period are <font color="blue">impacted by increases</font> or <font color="blue">decreases</font> in the <font color="blue">distribution channel</font>     inventory  levels</td>
    </tr>
    <tr>
      <td>We  cannot  <font color="blue">significant</font>ly control or influence the     <font color="blue">purchasing patterns</font> or <font color="blue">buying behavior</font> of <font color="blue">independent</font> <font color="blue">wholesalers</font> or end     users</td>
    </tr>
    <tr>
      <td>Although our wholesaler customers typically buy <font color="blue">product from</font> us only     as <font color="blue">necessary</font> to satisfy projected end user demand, we <font color="blue"><font color="blue">cannot predict</font> future</font>     <font color="blue">wholesalers</font>  buying  practices</td>
    </tr>
    <tr>
      <td>For example, <font color="blue">wholesalers</font> may engage in     <font color="blue">speculative purchases</font> of product in excess of the <font color="blue">current market demand</font> in     <font color="blue">anticipation</font> of <font color="blue">future price increases</font></td>
    </tr>
    <tr>
      <td>Accordingly, <font color="blue">purchases by</font> any given     customer, during any given period, may be above or below <font color="blue">actual patient</font>     demand  of  any  of  our products during the <font color="blue">same period</font>, resulting in     <font color="blue">fluctuations</font>  in  product  inventory  in  the <font color="blue">distribution channel</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">distribution channel</font> inventory levels <font color="blue">substantially</font> exceed end user demand,     we could experience <font color="blue">reduced revenue from sales</font> in <font color="blue">subsequent periods due</font> to     a reduction in end user demand</td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">customer base</font> is <font color="blue">highly concentrated</font></td>
    </tr>
    <tr>
      <td>Net sales     <font color="blue">generated from</font> our <font color="blue">largest three wholesale customers</font> <font color="blue">in the US </font>totaled     <font color="blue">approximately</font> 45prca of our total <font color="blue">consolidated</font> net sales for the year ended     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>If any of these <font color="blue">customers becomes insolvent</font> or disputes     payment of the amount it owes us, it <font color="blue">would adversely affect</font> our results of     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">successfully</font> acquire, in-license, develop and market     <font color="blue">additional</font> <font color="blue"><font color="blue">product candidate</font>s</font> or <font color="blue"><font color="blue">approved products</font> would impair</font> our ability     to grow and <font color="blue">could affect</font> the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As part of our <font color="blue">growth strategy</font>, we intend to acquire, in-license,     develop and market <font color="blue">additional</font> products and <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>Because we     neither  have,  nor  currently  intend to establish, internal research     <font color="blue">capabilities</font>,  we  are <font color="blue">dependent upon</font> <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     companies and other <font color="blue">researchers</font> to sell or <font color="blue">license products</font> to us</td>
    </tr>
    <tr>
      <td>The     success of this <font color="blue">strategy depends upon</font> our ability to identify, select and     acquire the right <font color="blue">pharmaceutical</font> <font color="blue"><font color="blue">product candidate</font>s</font> and products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">product candidate</font> we license or acquire may require <font color="blue">additional</font>     <font color="blue">development</font> efforts prior to <font color="blue">commercial sale</font>, including extensive clinical     testing  and  approval  by  the  FDA and applicable foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>All <font color="blue"><font color="blue">product candidate</font>s</font> are prone to the risks of failure     inherent in <font color="blue">pharmaceutical</font> product <font color="blue">development</font>, including the <font color="blue">possibility</font>     that the <font color="blue">product candidate</font> will not be shown to be <font color="blue"><font color="blue">sufficiently</font> safe</font> and     <font color="blue">effective</font>  for  approval  by <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Even where we are     successful in <font color="blue">gaining approval</font> for <font color="blue"><font color="blue">product candidate</font>s</font> we acquire, we cannot     assure  you  that  those  products  will  be  <font color="blue">manufacture</font>d or produced     <font color="blue">economically</font>,  <font color="blue">successfully</font>  <font color="blue">commercialize</font>d  or <font color="blue">widely accepted</font> in the     marketplace</td>
    </tr>
    <tr>
      <td>In addition, we will be required to integrate any acquired     products into our existing <font color="blue">operations</font>, including <font color="blue">satraplatin</font> and MGCD0103,     products that we have <font color="blue">only recently</font> acquired</td>
    </tr>
    <tr>
      <td>Managing the <font color="blue">development</font> of a     <font color="blue">new product entails numerous financial</font> and <font color="blue">operational risks</font>, including     <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">attracting qualified employees</font> to develop the products</td>
    </tr>
    <tr>
      <td>Proposing,  <font color="blue">negotiating</font> and <font color="blue">implementing</font> an <font color="blue">economically</font> viable     <font color="blue">acquisition</font> and licenses is a lengthy and <font color="blue">complex process</font></td>
    </tr>
    <tr>
      <td>Other companies,     including those with <font color="blue">substantially</font> greater financial, marketing and sales     resources, may compete with us for the <font color="blue">acquisition</font> of <font color="blue"><font color="blue">product candidate</font>s</font> and     <font color="blue">approved products</font></td>
    </tr>
    <tr>
      <td>We may not                                         29       _________________________________________________________________    [83]Table of <font color="blue">Contents       </font>be able to acquire the rights to <font color="blue">additional</font> <font color="blue"><font color="blue">product candidate</font>s</font> and approved     <font color="blue">products on terms</font> that we find acceptable, or at all</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">sufficient product <font color="blue">liability</font> insurance on</font>     <font color="blue">commercially reasonable terms</font> or <font color="blue">with adequate coverage</font> for thalidomide</td>
    </tr>
    <tr>
      <td>Historically, the vast majority of product <font color="blue">liability</font> insurers have     been unwilling to write any product <font color="blue">liability</font> coverage for thalidomide</td>
    </tr>
    <tr>
      <td>Although we currently have product <font color="blue">liability</font> coverage for thalidomide that     we believe is <font color="blue">appropriate</font>, if our sales of this <font color="blue">product grow</font> in the future,     our  current  <font color="blue">coverage may</font> be insufficient</td>
    </tr>
    <tr>
      <td>We may be unable to obtain     <font color="blue">additional</font> coverage on <font color="blue">commercially reasonable terms</font> if required, or our     <font color="blue">coverage may</font> be inadequate to <font color="blue">protect us</font> in the event claims are asserted     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>In addition, we might be unable to renew our <font color="blue">existing level</font> of     coverage  if there were a report of a <font color="blue">birth defect attributable</font> to the     <font color="blue">current use</font> of thalidomide, whether or not <font color="blue">sold by us</font></td>
    </tr>
    <tr>
      <td>Failure to achieve our sales targets or raise <font color="blue">additional</font> funds in the future     may require us to delay, reduce the scope of, or <font color="blue">eliminate one</font> or more of     our planned <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We will need to <font color="blue">generate greater sales</font> to maintain <font color="blue">profitability</font> on an     annual  basis</td>
    </tr>
    <tr>
      <td>The  product  <font color="blue">development</font>,  including <font color="blue"><font color="blue">clinical trial</font>s</font>,     <font color="blue">manufacturing</font> <font color="blue">development</font> and <font color="blue"><font color="blue">regulatory</font> approvals</font> of Vidaza, thalidomide,     <font color="blue">satraplatin</font> and MGCD0103, and the <font color="blue">acquisition</font> and <font color="blue">development</font> of <font color="blue">additional</font>     <font color="blue"><font color="blue">product candidate</font>s</font> by us will require a <font color="blue">commitment</font> of substantial funds</td>
    </tr>
    <tr>
      <td>Our     future capital <font color="blue">requirements</font> are <font color="blue">dependent upon</font> many factors and may be     <font color="blue">significant</font>ly greater than we expect</td>
    </tr>
    <tr>
      <td>We believe, <font color="blue">based on</font> our current operating plan, including anticipated     sales  of our products, that our cash, cash equivalents and short-term     <font color="blue">investment</font>s will be sufficient to fund our <font color="blue">operations</font> through at least the     <font color="blue">next twelve months</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">existing resources</font> are insufficient to satisfy     our liquidity <font color="blue">requirements</font> due to <font color="blue">slower than</font> anticipated sales of our     products or otherwise, or if we acquire <font color="blue">additional</font> products or product     <font color="blue">candidates</font>, we may need to sell <font color="blue">additional</font> equity or <font color="blue">debt securities</font></td>
    </tr>
    <tr>
      <td>If we     are unable to obtain this <font color="blue">additional</font> financing, we may be required to delay,     reduce the scope of, or <font color="blue">eliminate one</font> or more of our planned <font color="blue">development</font>,     <font color="blue">commercialization</font> or expansion <font color="blue">activities</font>, which <font color="blue">could harm</font> our financial     condition and operating results</td>
    </tr>
    <tr>
      <td>We may not be able to manage our business <font color="blue"><font color="blue">effective</font>ly</font> if we are unable to     attract and retain <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Our industry has experienced a high rate of turnover of <font color="blue">management</font>     personnel in <font color="blue">recent years</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly dependent on</font> our senior <font color="blue">management</font>     team, whose services are critical to the successful <font color="blue">implementation</font> of our     business strategies</td>
    </tr>
    <tr>
      <td>Each of our senior <font color="blue">executives</font> have entered into an     <font color="blue">employment</font> <font color="blue">agreement</font> with us for a term that runs until the <font color="blue">agreement</font> is     <font color="blue">otherwise terminated by us</font> or them</td>
    </tr>
    <tr>
      <td>These <font color="blue">employment</font> <font color="blue"><font color="blue">agreement</font>s</font> provide that     the <font color="blue">executive cannot compete with us</font> for a period of one year after his or     her <font color="blue">employment</font> with us is terminated</td>
    </tr>
    <tr>
      <td>If we lose the services of our senior     <font color="blue">management</font> or other <font color="blue">key employees</font>, our ability to <font color="blue">successfully</font> implement our     business <font color="blue">strategy could</font> be <font color="blue">seriously harmed</font></td>
    </tr>
    <tr>
      <td>We do not maintain key person     <font color="blue">life insurance on</font> any of the members of our senior <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Replacing </font>key     <font color="blue">employees may</font> be <font color="blue">difficult</font> and may take an <font color="blue">extended period</font> of time because     of the limited number of <font color="blue">individuals</font> in our <font color="blue">industry with</font> the breadth of     skills and experience required to develop, gain <font color="blue">regulatory</font> approval of and     <font color="blue">commercialize</font> products <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>to hire from this limited     pool is intense, and we may be unable to hire, train, retain or motivate     these <font color="blue">additional</font> <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">patent protection</font> for our <font color="blue">current products</font>, and we may not     be able to obtain, maintain and protect <font color="blue"><font color="blue">proprietary</font> rights</font> <font color="blue">necessary</font> for the     <font color="blue">development</font> and <font color="blue">commercialization</font> of our products or <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>Our  commercial  success  will  depend in part on obtaining and     maintaining a <font color="blue">strong <font color="blue">proprietary</font> position</font> for our <font color="blue">products both</font> in the US,     Europe and elsewhere</td>
    </tr>
    <tr>
      <td>We currently own or have <font color="blue">exclusive rights</font> to issued     patents and pending patent <font color="blue">application</font>s covering <font color="blue">thalidomide from</font> Celgene     Corporation, Vidaza, from Pfizer, Inc, <font color="blue">satraplatin</font> from <font color="blue">GPC Biotech AG </font>and     MGCD0103 from <font color="blue">MethylGene Inc</font></td>
    </tr>
    <tr>
      <td>We have limited patent                                         30       _________________________________________________________________    [84]Table of <font color="blue">Contents       </font>protection for Vidaza, <font color="blue">currently consisting</font> of <font color="blue">two issued patents covering</font>     <font color="blue">certain polymorphic forms</font> <font color="blue">of Vidaza </font>drug substance and methods of isolating     a crystalline form <font color="blue">of Vidaza </font>drug substance</td>
    </tr>
    <tr>
      <td>In addition, in May 2004 the     FDA awarded <font color="blue"><font color="blue">orphan drug</font> <font color="blue">exclusivity</font></font> to Vidaza for the treatment of MDS     patients, which lasts for <font color="blue">seven years from</font> the <font color="blue">date granted</font></td>
    </tr>
    <tr>
      <td>Given the     limited <font color="blue">patent protection</font> for Vidaza, we <font color="blue">must still rely</font> in large part on     <font color="blue"><font color="blue">orphan drug</font> <font color="blue">exclusivity</font></font> to protect and enhance our <font color="blue">competitive position</font> in     the US, and we will rely on <font color="blue">orphan drug</font> <font color="blue">designation</font> and data <font color="blue">exclusivity</font>     available in the EU, if and when Vidaza is approved for marketing in     Europe</td>
    </tr>
    <tr>
      <td>However, <font color="blue"><font color="blue">orphan drug</font> <font color="blue">exclusivity</font></font> does not prohibit <font color="blue">competitors</font> from     developing  or  marketing  <font color="blue">different</font>  drugs  for an <font color="blue">indication</font> or from     <font color="blue"><font color="blue">independent</font>ly</font>  developing  generic  versions  of  Vidaza for <font color="blue">different</font>     <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>In  addition,  while  we  are  selling  <font color="blue">thalidomide on</font> a     <font color="blue">compassionate</font>  use and <font color="blue">named patient basis</font>, we do not have <font color="blue">orphan drug</font>     <font color="blue">exclusivity</font>  and  we <font color="blue">must rely on</font> our use <font color="blue">patent protection</font> to prevent     <font color="blue">competitors</font> from selling thalidomide in our <font color="blue">markets until</font> we are granted a     <font color="blue">marketing authorization</font></td>
    </tr>
    <tr>
      <td>Finally, the primary European patents we have     licensed for <font color="blue">satraplatin</font> expire in 2009 and, therefore, we will be relying     on supplementary protection <font color="blue">certificate</font>s to extend <font color="blue">patent protection</font> and on     data <font color="blue">exclusivity</font> available <font color="blue">in the EU </font>if and when we achieve marketing     approval for this product</td>
    </tr>
    <tr>
      <td>We  also rely on protection derived from <font color="blue">trade secrets</font>, process     patents,  know-how  and  <font color="blue">technological</font>  innovation</td>
    </tr>
    <tr>
      <td>To  maintain  the     <font color="blue">confidentiality</font> of <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> information, we <font color="blue">generally</font>     seek  to  enter  into  <font color="blue">confidentiality</font>  <font color="blue"><font color="blue">agreement</font>s</font> with our employees,     <font color="blue">consultants</font> and <font color="blue">collaborators upon</font> the <font color="blue">commencement</font> of a <font color="blue">relationship with</font>     us</td>
    </tr>
    <tr>
      <td>However, we may not obtain these <font color="blue"><font color="blue">agreement</font>s</font> in all <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>In     addition, adequate remedies may not exist in the event of <font color="blue">unauthorized use</font>     or  <font color="blue">disclosure</font>  of this information</td>
    </tr>
    <tr>
      <td>The loss or exposure of our trade     secrets, know-how and other <font color="blue">proprietary</font> information <font color="blue">could harm</font> our operating     results, <font color="blue">financial condition</font> and <font color="blue">future growth prospects</font></td>
    </tr>
    <tr>
      <td>Furthermore,     <font color="blue">others may</font> have developed, or may develop in the future, <font color="blue">substantially</font>     similar or superior know-how and <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We intend to seek <font color="blue">patent protection</font> whenever it is available for any     products or <font color="blue"><font color="blue">product candidate</font>s</font> we acquire in the future</td>
    </tr>
    <tr>
      <td>However, any patent     <font color="blue">application</font>s for future products or pending <font color="blue">application</font>s for our existing     <font color="blue">products may</font> not issue as patents, and any <font color="blue">patent issued on such products</font>     may  be  challenged,  invalidated, held unenforceable or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Furthermore, the claims in patents that do ultimately issue on those patent     <font color="blue">application</font>s may not be <font color="blue">sufficiently</font> broad to prevent third parties from     <font color="blue">commercializing</font> <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>In addition, the laws of <font color="blue">various foreign</font>     countries in which we <font color="blue">compete may</font> not protect the <font color="blue">intellectual property on</font>     which we may rely to the <font color="blue">same extent as</font> do the laws of the US If we fail     to  obtain adequate <font color="blue">patent protection</font> for our products, our ability to     <font color="blue">compete could</font> be impaired</td>
    </tr>
    <tr>
      <td>We may undertake <font color="blue">acquisition</font>s in the future and any <font color="blue"><font color="blue">difficult</font>ies</font> from     <font color="blue">integrating</font> such <font color="blue">acquisition</font>s could damage our ability to attain or maintain     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We may acquire <font color="blue">additional</font> businesses, products or <font color="blue"><font color="blue">product candidate</font>s</font>     that  <font color="blue">complement</font>  or  augment our existing business</td>
    </tr>
    <tr>
      <td>To date, our only     experience in acquiring and <font color="blue">integrating</font> a business involved our <font color="blue">acquisition</font>     of <font color="blue">Laphal in March </font>2003</td>
    </tr>
    <tr>
      <td><font color="blue">Integrating </font>any newly acquired business or product     could be expensive and time-consuming</td>
    </tr>
    <tr>
      <td>We may not be able to integrate any     acquired business or product <font color="blue">successfully</font> or operate any acquired business     profitably</td>
    </tr>
    <tr>
      <td>Moreover, if we acquire <font color="blue">additional</font> businesses or products we     will incur <font color="blue">significant</font> <font color="blue">acquisition</font> costs and operating expenses, which could     harm our <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>In addition, we may need     to raise <font color="blue">additional</font> funds through public or <font color="blue">private debt</font> or <font color="blue">equity financing</font>     to make <font color="blue">acquisition</font>s, which may result in dilution for <font color="blue">stockholders</font> and the     incurrence of <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>Changes to financial <font color="blue">accounting</font> standards may affect our results of     <font color="blue">operations</font> and cause us to change our business practices</td>
    </tr>
    <tr>
      <td>We prepare our <font color="blue">financial statements</font> to conform with <font color="blue">generally</font> accepted     <font color="blue">accounting</font> principles, or GAAP, in the United States</td>
    </tr>
    <tr>
      <td>These <font color="blue">accounting</font>     principles  are subject to interpretation by the <font color="blue">American Institute </font>of     Certified Public Accountants, the Financial Accounting Standards Board, or     FASB,  the  SEC  and various bodies formed to promulgate and interpret     <font color="blue">appropriate</font> <font color="blue">accounting</font> policies</td>
    </tr>
    <tr>
      <td>A change in those <font color="blue">accounting</font> principles or     <font color="blue">interpretations</font> could have a <font color="blue">significant</font> effect on our reported financial     results and may affect our reporting of <font color="blue">transactions</font> completed before a     change is announced or adopted</td>
    </tr>
    <tr>
      <td>Changes to those rules or the questioning of     <font color="blue">current practices may adversely affect</font> our reported financial results or the     way we conduct our                                         31       _________________________________________________________________    [85]Table of <font color="blue">Contents       </font>business</td>
    </tr>
    <tr>
      <td>For example, <font color="blue">accounting</font> policies affecting certain aspects of our     business, including rules relating to <font color="blue">employee stock option grants</font>, have     <font color="blue">recently been revised</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, the FASB issued a revision of     SFAS Nodtta 123,  “Accounting for Stock-Based Compensation,” <font color="blue">which amends</font>     SFAS Nodtta 123  to  require the <font color="blue">recognition</font> of <font color="blue">employee stock options as</font>     compensation <font color="blue">based on</font> their <font color="blue"><font color="blue">fair value</font> at</font> the time of grant (with limited     <font color="blue">exceptions</font>)</td>
    </tr>
    <tr>
      <td>As a result of these new rules, on January 1, 2006 we changed     our  <font color="blue">accounting</font> policies and <font color="blue">will thereafter record</font> an expense for our     stock-based compensation plans <font color="blue">based on</font> the estimated <font color="blue">fair value</font> of options     granted, which will result in <font color="blue">additional</font> <font color="blue">accounting</font> charges as described in     Management’s Discussion and Analysis of Financial Condition and Results of     Operations — Recently Issued Accounting Standards</td>
    </tr>
    <tr>
      <td>Our business is subject to economic, political, <font color="blue">regulatory</font> and other risks     <font color="blue">associated with international sales</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Since we sell our products in Europe, Australia and many <font color="blue">additional</font>     countries, our business is subject to risks associated with conducting     business  <font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td>We anticipate that sales from international     <font color="blue">operations</font> will continue to represent a substantial portion of our total     sales</td>
    </tr>
    <tr>
      <td>In addition, a number of our suppliers are <font color="blue">located outside</font> the United     States</td>
    </tr>
    <tr>
      <td>Accordingly, our future results could be <font color="blue">harmed by</font> a variety of     factors, including:         •  <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue"><font color="blue">compliance with</font> foreign laws</font> and <font color="blue">regulations</font>;         •  changes in foreign <font color="blue">regulations</font> and customs;         •  changes in <font color="blue">foreign currency exchange rates</font> and <font color="blue">currency controls</font>;         •  changes in a specific country’s or region’s political or economic     <font color="blue">environment</font>;         •  trade protection measures, import or export licensing <font color="blue">requirements</font> or     other <font color="blue">restrictive actions by</font> the US or foreign <font color="blue"><font color="blue">government</font>s</font>;         •  negative <font color="blue">consequences</font> from changes in tax laws;         •  <font color="blue"><font color="blue">difficult</font>ies</font> associated with staffing and managing foreign <font color="blue">operations</font>;         •  longer <font color="blue">accounts</font> receivable cycles in some countries; and         •  differing labor <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry       Our ability to <font color="blue">generate sales from</font> our products will depend on <font color="blue">reimbursement</font>     and <font color="blue">drug pricing policies</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our ability to achieve acceptable levels of <font color="blue">reimbursement</font> for drug     <font color="blue">treatments</font> by <font color="blue">government</font>al <font color="blue">authorities</font>, private health insurers and other     <font color="blue">organizations</font>  will  have  an  effect  on  our ability to <font color="blue">successfully</font>     <font color="blue">commercialize</font>,  and  attract  <font color="blue">collaborative</font>  partners to invest in the     <font color="blue">development</font>  of,  product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>The Medicare Prescription Drug,     Improvement, and Modernization Act of 2003 together with rulemaking by the     Centers for Medicare and Medicaid Services, or CMS, changed the <font color="blue">methodology</font>     for  Medicare <font color="blue">reimbursement</font> of <font color="blue">pharmaceutical</font> products administered in     <font color="blue">physician offices</font> and hospital outpatient <font color="blue">facilities</font>, including Vidaza and     Innohep</td>
    </tr>
    <tr>
      <td>Under these <font color="blue">regulations</font>, <font color="blue">reimbursement</font>s are the average selling     price, or ASP, of a product plus 6prca, rather than a <font color="blue">specified discount from</font>     the  average  wholesale  price,  or  AWP,  as was the <font color="blue">case under prior</font>     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The ASP-based <font color="blue">reimbursement</font> regime <font color="blue">generally</font> reduced the     <font color="blue">reimbursement</font> physicians receive under Medicare for most office-administered     injectable drugs, including Vidaza and Innohep</td>
    </tr>
    <tr>
      <td>The changes made to date     have  not  yet  resulted in an adverse affect on <font color="blue">reimbursement</font> for our     products,  however  we  <font color="blue">cannot predict</font> the impact, if any, that future     <font color="blue">reimbursement</font> policies will adversely affect product use by physicians,     <font color="blue">thereby reducing</font> our sales for these products</td>
    </tr>
    <tr>
      <td>In other countries, <font color="blue">particularly</font> the countries of the European Union,     the pricing of <font color="blue">prescription</font> <font color="blue">pharmaceutical</font>s and the level of <font color="blue">reimbursement</font>     are  subject  to  strict  <font color="blue"><font color="blue">government</font>al control</font></td>
    </tr>
    <tr>
      <td>We cannot be sure that     <font color="blue">reimbursement</font> in the US, Europe or elsewhere will be available for any     products we may develop or, if                                         32       _________________________________________________________________    [86]Table of <font color="blue">Contents       </font>already available, will not be decreased or eliminated in the future</td>
    </tr>
    <tr>
      <td>If     <font color="blue">reimbursement</font> is not available or is <font color="blue">available only at</font> limited levels, we     may not be able to <font color="blue">successfully</font> <font color="blue">commercialize</font> our products, and may not be     able to obtain a satisfactory <font color="blue">financial return on</font> our products</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">payers increasingly</font> are <font color="blue">challenging prices charged</font> for     <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>Also, the trend toward managed <font color="blue">health care</font> in     the  US  and  the  changes  in health insurance programs, as well as     <font color="blue">legislative</font> proposals to reform <font color="blue">health care</font> or reduce <font color="blue">government</font> insurance     programs, may result in lower prices for <font color="blue">pharmaceutical</font> products, including     any products that may be offered by us</td>
    </tr>
    <tr>
      <td>Cost-cutting measures that health     <font color="blue">care providers</font> are <font color="blue">instituting</font>, and the effect of any <font color="blue"><font color="blue">health care</font> reform</font>,     <font color="blue">could harm</font> our ability to sell any products that are <font color="blue">successfully</font> developed     by us and <font color="blue">approved by</font> <font color="blue">regulators</font></td>
    </tr>
    <tr>
      <td>Moreover, we are unable to predict what     <font color="blue">additional</font> <font color="blue">legislation</font> or regulation, if any, relating to the <font color="blue">health care</font>     industry or third-party coverage and <font color="blue">reimbursement</font> may be enacted in the     future or what effect this <font color="blue">legislation</font> or <font color="blue">regulation would</font> have on our     business</td>
    </tr>
    <tr>
      <td>In the event that <font color="blue">government</font>al <font color="blue">authorities</font> enact <font color="blue">legislation</font> or     adopt <font color="blue">regulations</font> that affect third-party coverage and <font color="blue">reimbursement</font>, demand     for our <font color="blue">products may</font> be reduced thereby harming our sales and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If product <font color="blue">liability</font> lawsuits are brought <font color="blue">against us</font>, we may incur     substantial <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical testing</font> and <font color="blue">commercialization</font> of <font color="blue">pharmaceutical</font> products     involves <font color="blue">significant</font> exposure to product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>If <font color="blue">losses from</font>     such  claims  exceed  our  <font color="blue">liability</font>  <font color="blue">insurance coverage</font>, we may incur     substantial <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Whether or not we were ultimately successful in     product <font color="blue">liability</font> <font color="blue">litigation</font>, such <font color="blue">litigation</font> could consume substantial     amounts of our financial and managerial resources, and might result in     adverse publicity, all of which would impair our business</td>
    </tr>
    <tr>
      <td>We may not be     able to maintain our <font color="blue">clinical trial</font> insurance or product <font color="blue">liability</font> insurance     at  an  acceptable cost, if at all, and this <font color="blue">insurance may</font> not provide     <font color="blue">adequate coverage against potential</font> claims or losses</td>
    </tr>
    <tr>
      <td>If we are required to     pay  a  product  <font color="blue">liability</font> claim, we may not have <font color="blue">sufficient financial</font>     resources to complete <font color="blue">development</font> or <font color="blue">commercialization</font> of any of our product     <font color="blue">candidates</font> and our business and results of <font color="blue">operations</font> will be harmed</td>
    </tr>
    <tr>
      <td>If our promotional <font color="blue">activities</font> fail to <font color="blue">comply with</font> the <font color="blue">regulations</font> and     <font color="blue">guidelines</font> of the various relevant <font color="blue">regulatory</font> agencies, we may be subject to     warnings or <font color="blue">enforcement action</font> that <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font><font color="blue">may prescribe drugs</font> for uses that are not described in the     product’s  labeling for uses that <font color="blue">differ from</font> those tested in clinical     studies and <font color="blue">approved by</font> the FDA or similar <font color="blue">regulatory</font> <font color="blue">authorities</font> in other     countries</td>
    </tr>
    <tr>
      <td>These “off-label” uses are <font color="blue">common across medical specialties</font> and     <font color="blue">may constitute</font> the <font color="blue">best treatment</font> for many patients in varied <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities</font> <font color="blue">generally</font> do not regulate the behavior of physicians     in their choice of <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities</font> do, however, restrict     <font color="blue">communications on</font> the subject of off-label use</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font><font color="blue">cannot actively</font>     <font color="blue">promote approved drugs</font> for off-label uses, but in some <font color="blue">countries outside</font> of     the EU, including the US, they <font color="blue">may <font color="blue">disseminate</font></font> to <font color="blue">physicians articles</font>     published  in peer-reviewed journals, like “<font color="blue">The New England Journal </font>of     Medicine”  and  “The  Lancet,” that discuss off-label uses of approved     products</td>
    </tr>
    <tr>
      <td>To the extent allowed, we <font color="blue">may <font color="blue">disseminate</font></font> peer-reviewed articles     on our products to our physician customers</td>
    </tr>
    <tr>
      <td>We believe our promotional     <font color="blue">activities</font> are currently in <font color="blue">compliance with</font> the <font color="blue">regulations</font> and <font color="blue">guidelines</font>     of  the  various  <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>If, however, our promotional     <font color="blue">activities</font> fail to <font color="blue">comply with</font> these <font color="blue">regulations</font> or <font color="blue">guidelines</font>, we may be     subject to <font color="blue">warnings from</font>, or <font color="blue">enforcement action</font> by, these <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Furthermore, if the discussion of off-label use in peer-reviewed journals or     the <font color="blue">dissemination</font> of these articles is prohibited, it <font color="blue">may harm demand</font> for     our products</td>
    </tr>
    <tr>
      <td>We are subject to numerous complex <font color="blue">regulatory</font> <font color="blue">requirements</font> and failure to     <font color="blue">comply with</font> these <font color="blue">regulations</font>, or the cost of <font color="blue">compliance with</font> these     <font color="blue">regulations</font>, may harm our business</td>
    </tr>
    <tr>
      <td>The testing, <font color="blue">development</font> and <font color="blue">manufacturing</font> of our products are subject     to regulation by numerous <font color="blue">government</font>al <font color="blue">authorities</font> in the US, Europe and     elsewhere</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> govern or affect the testing, <font color="blue">manufacture</font>,     safety,  labeling,  storage, record-keeping, approval, advertising and     promotion of our products and <font color="blue"><font color="blue">product candidate</font>s</font>, as well as safe working     <font color="blue">conditions</font> and the <font color="blue">experimental use</font> of animals</td>
    </tr>
    <tr>
      <td>Non<font color="blue">compliance with</font> any     applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> can result in refusal of the <font color="blue">government</font>     to <font color="blue">approve products</font> for marketing, criminal prosecution and fines, recall or     seizure of products, total or <font color="blue">partial suspension</font> of                                         33       _________________________________________________________________    [87]Table of <font color="blue">Contents       </font>production, prohibitions or <font color="blue">limitations</font> on the <font color="blue">commercial sale</font> of products     or  refusal  to  allow  us  to <font color="blue">enter into</font> supply contracts</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>    <font color="blue">authorities</font> typically have the authority to <font color="blue">withdraw approvals</font> that have     <font color="blue">been previously granted</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> <font color="blue">requirements</font> relating to the <font color="blue">manufacturing</font>, testing,     and marketing of our <font color="blue">products may</font> change from time to time</td>
    </tr>
    <tr>
      <td>For example, at     present, member states <font color="blue">in the EU </font>are in the process of <font color="blue">incorporating into</font>     their <font color="blue">domestic laws</font> the <font color="blue">provisions contained</font> <font color="blue">in the EU </font>Directive on the     <font color="blue">implementation</font> of good <font color="blue">clinical practice</font> in the conduct of <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Directive </font>imposes more onerous <font color="blue">requirements</font> in relation to certain     aspects of the conduct of <font color="blue"><font color="blue">clinical trial</font>s</font> than are currently in place in     many member states</td>
    </tr>
    <tr>
      <td>This may impact our ability to conduct <font color="blue"><font color="blue">clinical trial</font>s</font>     and the ability of <font color="blue">independent</font> investigators to conduct their own research     <font color="blue">with support from us</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Common Stock       Our <font color="blue">certificate</font> of incorporation, our bylaws, <font color="blue">Delaware </font>law and our     <font color="blue">employment</font> <font color="blue"><font color="blue">agreement</font>s</font> with members of our senior <font color="blue">management</font> contain     provisions that could discourage, delay or prevent a change in control or     <font color="blue">management</font> of Pharmion</td>
    </tr>
    <tr>
      <td>Our  amended and restated <font color="blue">certificate</font> of incorporation, bylaws,     <font color="blue">Delaware </font>law and our <font color="blue">employment</font> <font color="blue"><font color="blue">agreement</font>s</font> with members of senior <font color="blue">management</font>     <font color="blue">contain provisions which could delay</font> or prevent a <font color="blue"><font color="blue">third party</font> from</font> acquiring     shares of our <font color="blue">common stock</font> or <font color="blue">replacing members</font> of our board of <font color="blue">directors</font>,     each of which <font color="blue">certificate</font> of <font color="blue">incorporation provisions</font> can only be amended or     <font color="blue">repealed upon</font> the consent of 80prca of our <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>Our amended and     restated <font color="blue">certificate</font> of <font color="blue">incorporation allows</font> our board of <font color="blue">directors</font> to issue     up to 10cmam000cmam000 shares of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>The board can determine the     price,  rights, preferences and privileges of those <font color="blue">shares without</font> any     further  vote or <font color="blue">action by</font> the <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>As a result, our board of     <font color="blue">directors</font> could make it <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of     our <font color="blue">outstanding voting stock</font>, for <font color="blue">example by adopting</font> a <font color="blue">stockholders</font>’ rights     plan</td>
    </tr>
    <tr>
      <td>Our amended and restated <font color="blue">certificate</font> of <font color="blue">incorporation also provides</font>     that the members of the board are <font color="blue">divided into three classes</font></td>
    </tr>
    <tr>
      <td>Each year the     terms of <font color="blue">approximately</font> one-third of the <font color="blue">directors</font> will expire</td>
    </tr>
    <tr>
      <td>Our bylaws do     not permit our <font color="blue">stockholders</font> to call a <font color="blue">special meeting</font> of <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Under     </font>the bylaws, only our Chief Executive Officer, Chairman of the Board or a     majority of the board of <font color="blue">directors</font> are able to call <font color="blue">special meeting</font>s</td>
    </tr>
    <tr>
      <td>The     staggering of <font color="blue">directors</font>’ terms of office and the <font color="blue">limitation on</font> the ability     of  <font color="blue">stockholders</font>  to  call a <font color="blue">special meeting</font> may make it <font color="blue">difficult</font> for     <font color="blue">stockholders</font> to remove or replace the board of <font color="blue">directors</font> should they desire     to do so</td>
    </tr>
    <tr>
      <td>Since <font color="blue">management</font> is <font color="blue">appointed by</font> the board of <font color="blue">directors</font>, any     <font color="blue">inability</font> to effect a change in the <font color="blue">board may</font> result in the <font color="blue">entrenchment</font> of     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">bylaws also</font> require that <font color="blue">stockholders</font> give advance notice to     our  <font color="blue">Secretary </font>of any <font color="blue">nominations</font> for director or other business to be     brought by <font color="blue">stockholders</font> at any <font color="blue">stockholders</font>’ meeting</td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may</font>     delay or prevent changes of control or <font color="blue">management</font>, either by third parties     or by <font color="blue">stockholders</font> seeking to change control or <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>We are also subject to the anti-takeover provisions of Section 203 of     the <font color="blue">Delaware </font>General Corporation Law</td>
    </tr>
    <tr>
      <td>Under these provisions, if anyone     becomes an “<font color="blue">interested stockholder</font>,” we may not <font color="blue">enter into</font> a “business     combination” with that person for <font color="blue">three years without special approval</font>,     <font color="blue">which could discourage</font> a <font color="blue"><font color="blue">third party</font> from</font> making a <font color="blue">takeover offer</font> and could     delay  or  prevent  a  change of control</td>
    </tr>
    <tr>
      <td>For purposes of Section 203,     “<font color="blue">interested stockholder</font>” means, <font color="blue">generally</font>, someone owning 15prca or more of our     <font color="blue">outstanding voting stock</font> or an affiliate of ours that owned 15prca or more of     our <font color="blue">outstanding voting stock</font> during the <font color="blue">past three years</font>, subject to certain     <font color="blue">exceptions</font> as described in Section 203</td>
    </tr>
    <tr>
      <td>The <font color="blue">employment</font> <font color="blue"><font color="blue">agreement</font>s</font> with members of our senior <font color="blue">management</font>     provide that <font color="blue">certain benefits will</font> be payable to the <font color="blue">executives</font> in the event     we  undergo a change in control and the <font color="blue">termination</font> of the executive’s     <font color="blue">employment</font> within two years after such change in control for any reason     other  than  for  cause, disability, death, normal retirement or early     retirement</td>
    </tr>
    <tr>
      <td>34       _________________________________________________________________    [88]Table of <font color="blue">Contents       </font>Our stock price has been and <font color="blue">may continue</font> to be volatile and your <font color="blue">investment</font>     in our <font color="blue">common stock</font> could suffer a decline in value              Our  common  stock has been and in the <font color="blue">future may</font> be subject to     substantial  price  <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>During  the period January 1, 2005 to     <font color="blue">December </font>31, 2005, the closing price of our <font color="blue">common stock</font> ranged from a high     of dlra44dtta55 per share to a low of dlra16dtta49 per share</td>
    </tr>
    <tr>
      <td>Some <font color="blue">specific factors</font> that could have a <font color="blue">significant</font> effect on our     <font color="blue">common stock</font> <font color="blue">market price</font> include:         •  actual or anticipated <font color="blue">fluctuations</font> in our operating results;         •  our <font color="blue">announcement</font>s or our <font color="blue">competitors</font>’ <font color="blue">announcement</font>s of <font color="blue">clinical trial</font>     results or <font color="blue">regulatory</font> approval of <font color="blue">new products</font>;         •  changes in our <font color="blue">growth rates</font> or our <font color="blue">competitors</font>’ <font color="blue">growth rates</font>;         •  the timing or results of <font color="blue">regulatory</font> <font color="blue">submissions</font> or <font color="blue">actions with respect</font>     to our products;         •  public concern as to the safety of our products;         •  changes in <font color="blue">health care</font>, drug pricing or <font color="blue">reimbursement</font> policies in a     country where we sell our products;         •  our <font color="blue">inability</font> to raise <font color="blue">additional</font> capital;          •   our ability to grow through successful product <font color="blue">acquisition</font>s and     in-licensing <font color="blue"><font color="blue">agreement</font>s</font>;         •  <font color="blue">conditions</font> of the <font color="blue">pharmaceutical</font> industry or in the <font color="blue">financial markets</font>     or economic <font color="blue">conditions</font> in general; and         •  changes in <font color="blue">stock market analyst recommendations</font> regarding our common     stock, other <font color="blue">comparable companies</font> or the <font color="blue">pharmaceutical</font> industry <font color="blue">generally</font></td>
    </tr>
  </tbody>
</table>